- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00858338
Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer
10. marts 2016 opdateret af: NYU Langone Health
Phase-II Study of Adjuvant Intraperitoneal FUDR Treatment Added to Chemoradiation (5-fluorouracil/Leucovorin Plus Total Dose 4500 cGy of External Beam Radiotherapy) in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma (R0 Resection and at Least D1 Lymph-node Dissection)
This study is to evaluate the efficacy and safety of addition of intraperitoneal (ip) Floxuridine to adjuvant chemoradiation therapy for patients under-going potentially curative stomach resection.
Studieoversigt
Status
Afsluttet
Intervention / Behandling
Detaljeret beskrivelse
Most patients diagnosed with stomach cancer in the US fail to be cured by gastric resection, and most trials of adjuvant chemotherapy do not improve survival rates.
However, it has shown that chemo-radiotherapy can substantially increase survival rates after gastric resection in a recent intergroup randomized study (INT 0116) that used adjuvant chemoradiation of 5-fluorouracil (5-FU) and leucovorin concurrently with total dose of 4500 cGy of external-beam radiation treatment (RT) to the abdominal tumor nodal field in patients with resected, locally advanced gastric cancer.
However, since the most common recurrences in both arms (surgery only vs. surgery followed by chemoradiation) were regional, typically abdominal carcinomatosis, this may indicate the need for adjuvant ip floxuridine to be added to adjuvant chemoradiation.
Our experience for ip floxuridine leads us to hypothesize that the addition of this type of therapy to adjuvant chemoradiation may further increase the cure-rate for patient under-going potentially curative gastric resection.
It seems important to convincingly demonstrate the effect of ip floxuridine treatment combined with the chemoradiation regimen.
This became the basis for the design of this Phase II study, which will test the toxicity and efficacy of ip floxuridine added to chemo-radiation of the INT 0116 study.
The protocol is to be completed in three years, and it may become a springboard for planning and initiation of a pivotal multi-institutional trials.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
28
Fase
- Fase 2
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
New York
-
New York, New York, Forenede Stater, 10016
- Bellevue Hospital
-
New York, New York, Forenede Stater, 10016
- NYU Tisch Hospital
-
New York, New York, Forenede Stater, 10016
- NYU Cancer Center
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Eligibility to the protocol is established following complete evaluation specified under 9.2 of the study protocol. This evaluation includes the diagnosis and disease stage. Untreated patients with histologically documented gastric/GEJ carcinoma stages IB-IV (Mo), become eligible.
- Patients who underwent emergency surgery for indications such as gastrointestinal obstruction, perforation or hemorrhage, or patients with surgery already performed, are eligible as long as the surgery is considered curative (Ro) as specified in section 9.3 of the study protocol.
- A device for adjuvant ip chemotherapy has to be in situ, placed during the surgery or early (1-3 weeks) thereafter. Time elapsed since the surgery must not exceed 4 weeks.
- Patient's diagnosis and staging, based on postoperative pathological findings, has to confirm stage IB-IV Mo adenocarcinoma of the stomach or GEJ. Patients and their clinical records must be evaluated by protocol surgical, radiation and medical oncologists, and sections of resected primary tumor and lymph nodes by protocol surgical pathologist.
- Each patient has to undergo pretreatment evaluation, sign Informed Consent, and be registered.
- Patients at least 18 years of age with performance status 0-2 (Appendix B of the study protocol).
- An adequate bone-marrow reserve (segmented neutrophils and bands, at least 1,500/ mmL, thrombocytes at least 100,000 /mmL, hemoglobin at least 9 gm/dL).
- Preserved liver and renal function (total serum bilirubin <2 mg/dL, SGOT/SGPT not greater than 2.5x the upper limit of normal, alkaline phosphatase not greater than 2.5x the upper limit of normal, BUN not greater than 30 mg/dL, creatinine concentration not greater than 1.5 mg/dL or creatinine clearance >60 mL/min), and negative BHcG in females of reproductive potential, are required.
- Patient must have evidence of at least unilateral renal function as established by CT scan with contrast or nephrogram. If only one kidney is present, at least two thirds of the functioning kidney must be excluded from any radiation port.
- The prothrombin time, activated partial thromboplastin time, and thrombin time should be within the range of normal values.
- All patients and records must be evaluated by a Surgical, Radiation and Medical Oncologists within one month before their entry to this protocol. There should be a reasonable assurance that patient will be available for planned post-treatment follow-up.
- Each patient must sign the Informed Consent Form.
Exclusion Criteria:
- Patients who do not meet criteria specified in inclusion criteria, and patients who have received prior RT, chemotherapy or immunotherapy.
- Patients with another active invasive malignancy. Adequately treated basal cell or squamous cell skin cancer, in-situ cervix cancer, or other cancers the patient has been free for at least 5 years, are acceptable.
- Patients with active or uncontrolled infection including HIV.
- Patients with psychiatric disorders that would interfere with their consent.
- Pregnant and nursing patients. Patients of reproductive age may not participate unless they agree to use an effective contraceptive method.
- Patients with any other severe concurrent disease, which in judgment of protocol investigators would make the patient inappropriate for this study.
- Protocol patients who did not receive ip FUDR treatment for complications related to catheter insertion or maintenance. However, these patients may still undergo off-protocol chemoradiation.
- Patients who did not sign written informed consent.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
toxicity of IP FUDR after surgery prior to chemoradiation
Tidsramme: 6 months
|
6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
overall survival
Tidsramme: up to 10 years
|
every 4 months the first year after treatment; every 6 months 2nd and 3rd year; yearly thereafter up to a total 10 years
|
up to 10 years
|
Time to relapse, disease specific survival
Tidsramme: up to 10 years
|
every 4 months the first year after treatment; every 6 months 2nd and 3rd year; yearly thereafter up to a total 10 years
|
up to 10 years
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Hjælpsomme links
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. december 2002
Primær færdiggørelse (Faktiske)
1. marts 2007
Studieafslutning (Faktiske)
1. februar 2012
Datoer for studieregistrering
Først indsendt
6. marts 2009
Først indsendt, der opfyldte QC-kriterier
6. marts 2009
Først opslået (Skøn)
9. marts 2009
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
11. marts 2016
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
10. marts 2016
Sidst verificeret
1. marts 2016
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Neoplasmer
- Neoplasmer efter sted
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Gastrointestinale sygdomme
- Mavesygdomme
- Neoplasmer i maven
- Molekylære mekanismer for farmakologisk virkning
- Antimetabolitter, Antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Floxuridin
Andre undersøgelses-id-numre
- 02-51 (H 10610)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Potentially curative surgery
-
Diakonessenhuis, UtrechtRekrutteringLivskvalitet | Søvnapnø, obstruktivHolland
-
Royal Surrey County Hospital NHS Foundation TrustUkendtLivmoderhalskræft | Æggelederkræft | Peritoneal kræft | Neoplasma i æggestokkene | Ovarie neoplasma epitelialDet Forenede Kongerige
-
The Second Hospital of Shandong UniversityRekrutteringLungekræft | Kirurgi | ERASKina
-
University of Colorado, DenverRekrutteringForbedret restitution efter operation | Gynækologisk sygdomForenede Stater
-
University Hospital, GrenobleAfsluttet
-
Grupo Español de Rehabilitación MultimodalInstituto de Salud Carlos III; Instituto de Investigación Sanitaria AragónRekrutteringStørre operationSpanien
-
ARCAGY/ GINECO GROUPRekrutteringOvariekræft Stadium IIIC | Ovariekræft Stadium IV | Ovariekræft Stadium IIIbFrankrig
-
Bournemouth UniversityStryker Orthopaedics; Nuffield Health Bournemouth; Orthopaedic Research InstituteRekrutteringSlidgigt, HofteDet Forenede Kongerige
-
Medacta International SARekrutteringRekonstruktion af forreste korsbånd (ACL).Østrig, Tyskland
-
AGO Study GroupCancer Research UK; ARCAGY/ GINECO GROUP; Grupo Español de Investigación... og andre samarbejdspartnereAfsluttetLivmoderhalskræft | Æggelederkræft | Peritoneal hulrumskræftSpanien, Frankrig, Danmark, Belgien, Tyskland, Østrig, Kina, Italien, Korea, Republikken, Norge, Sverige, Det Forenede Kongerige